Santen and Merck Sign Licensing Agreement for Tafluprost Treatment for Glaucoma and Ocular Hypertension
April 17, 2009
Santen Pharmaceutical of Japan announced earlier this week that it had signed a worldwide licensing agreement granting Merck exclusive rights to market tafluprost in North America (among other territories).
Tafluprost is a prostaglandin analogue for reduction of intraocular pressure in primary open angle glaucoma and ocular hypertension. Tafluprost is currently an investigational compound in the United States. If Tafluprost is approved in the United States, Santen will have the option to co-promote the product in the United States.
Read the full press release.
You might also enjoy...
- Do Travoprost Eye Drops Produce Lower Diurnal IOP Than Tafluprost Eye Drops?
- New Lumigan Eye Drop Formulation for Glaucoma From Allergan Approved by FDA
- Does Delaying Drug Treatment of Patients With Ocular Hypertension Increase the Risk of Glaucoma?
- Aton Pharma Acquires Marketing Rights to Preservative-Free Timolol Product Line from Merck
- Inotek Pharmaceuticals Presentations at ARVO 2009
Comments
Jump down to form below to submit your own comments
One Response to “Santen and Merck Sign Licensing Agreement for Tafluprost Treatment for Glaucoma and Ocular Hypertension”
Trackback URL
http://eyedocnews.com/00877-santen-and-merck-sign-licensing-agreement-for-tafluprost-treatment-for-glaucoma-and-ocular-hypertension/trackback/
Have insights to contribute? Please submit your comment below
yet another prostaglandin!